Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy
Kim IY, Mitrofanova A, Panja S, Sterling J, Srivastava A, Kim J, Kim S, Singer EA, Jang TL, Ghodoussipour S, Saraiya B, Mayer T, Sabaawy HE, Yuh B, Byun SS, Kim WJ, Horie S. Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy. Prostate International 2022, 10: 75-79. PMID: 35510081, PMCID: PMC9035380, DOI: 10.1016/j.prnil.2022.03.001.Peer-Reviewed Original ResearchCytoreductive radical prostatectomyPhase 1 clinical trialLong-term outcomesProstate cancerRadical prostatectomyOncologic outcomesSystemic therapyClinical trialsMulticenter phase 1 trialLong-term oncologic outcomesAndrogen deprivation therapyPrimary end pointEvidence of diseaseMajor complication rateCombination of surgeryMajor inclusion criteriaPhase 1 trialMetastatic prostate cancerB prostate cancerTumor necrosis factorLong-term useMinority of menDeprivation therapyM1 diseaseClavien-Dindo